HUP0300032A2 - Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition - Google Patents

Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition

Info

Publication number
HUP0300032A2
HUP0300032A2 HU0300032A HUP0300032A HUP0300032A2 HU P0300032 A2 HUP0300032 A2 HU P0300032A2 HU 0300032 A HU0300032 A HU 0300032A HU P0300032 A HUP0300032 A HU P0300032A HU P0300032 A2 HUP0300032 A2 HU P0300032A2
Authority
HU
Hungary
Prior art keywords
alpha
prevention
treatment
adrenoreceptor
preparation
Prior art date
Application number
HU0300032A
Other languages
Hungarian (hu)
Inventor
Mia Engstroem
Liisa Huovinen
Sari Kalliokoski
Leila Kelanne
Eeva-Liisa Savola
Siegfried Wurster
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/en
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of HUP0300032A2 publication Critical patent/HUP0300032A2/en
Publication of HUP0300032A3 publication Critical patent/HUP0300032A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A találmány az (A), (B), (C), (D) vagy (E) képletű vegyületekre ésezek gyógyászatilag elfogadható sóira vonatkozik, amelyekgyógyszerként alkalmazhatók. A találmány kiterjed az alfa-2B-adrenoreceptor antagonisták alkalmazására emlősöknél alfa-2B-adrenoreceptor által közvetített betegségek kezelésére vagymegelőzésére alkalmas gyógyszerkészítmény előállítására. ÓThe invention relates to compounds of formula (A), (B), (C), (D) or (E) and their pharmaceutically acceptable salts, which can be used as medicine. The invention covers the use of alpha-2B-adrenoreceptor antagonists for the production of pharmaceutical preparations suitable for the treatment or prevention of diseases mediated by alpha-2B-adrenoreceptors in mammals. HE

HU0300032A 2000-02-11 2001-02-07 Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition HUP0300032A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
FI20000303A FI20000303A0 (en) 2000-02-14 2000-02-14 Compounds Useful for the Treatment or Prevention of Alpha-2B Adrenoceptor Mediated Disease
PCT/FI2001/000105 WO2001058454A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Publications (2)

Publication Number Publication Date
HUP0300032A2 true HUP0300032A2 (en) 2003-05-28
HUP0300032A3 HUP0300032A3 (en) 2006-01-30

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300032A HUP0300032A3 (en) 2000-02-11 2001-02-07 Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition

Country Status (22)

Country Link
EP (1) EP1253926A1 (en)
JP (1) JP2003522148A (en)
KR (1) KR20020080413A (en)
AU (1) AU780802B2 (en)
BR (1) BR0108221A (en)
CA (1) CA2399421A1 (en)
CZ (1) CZ20022884A3 (en)
EA (1) EA200200846A1 (en)
EE (1) EE200200435A (en)
GE (1) GEP20043356B (en)
HR (1) HRP20020746A2 (en)
HU (1) HUP0300032A3 (en)
IL (1) IL151017A0 (en)
IS (1) IS6476A (en)
MX (1) MXPA02007454A (en)
MY (1) MY133957A (en)
NO (1) NO20023773L (en)
NZ (1) NZ520500A (en)
PL (1) PL357872A1 (en)
SK (1) SK11472002A3 (en)
WO (1) WO2001058454A1 (en)
YU (1) YU59102A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000615A (en) * 2001-07-20 2004-04-20 Juvantia Pharma Ltd Oy Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor.
FI116940B (en) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy New N-pyrimidinyl para-aminobenzenesulfonamide derivatives as Alpha-2B adrenoceptor antagonists, useful for treating e.g. coronary heart disease, myocardial infarction, angina, restenosis and hypertension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
KR20020080413A (en) 2002-10-23
HUP0300032A3 (en) 2006-01-30
PL357872A1 (en) 2004-07-26
MXPA02007454A (en) 2004-08-23
NZ520500A (en) 2005-01-28
CZ20022884A3 (en) 2003-02-12
YU59102A (en) 2005-11-28
WO2001058454A1 (en) 2001-08-16
MY133957A (en) 2007-11-30
JP2003522148A (en) 2003-07-22
AU3551001A (en) 2001-08-20
BR0108221A (en) 2003-03-05
AU780802B2 (en) 2005-04-21
NO20023773D0 (en) 2002-08-09
EP1253926A1 (en) 2002-11-06
CA2399421A1 (en) 2001-08-16
HRP20020746A2 (en) 2004-12-31
EA200200846A1 (en) 2002-12-26
IL151017A0 (en) 2003-02-12
IS6476A (en) 2002-07-19
NO20023773L (en) 2002-08-09
EE200200435A (en) 2003-12-15
GEP20043356B (en) 2004-04-13
SK11472002A3 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
CY1115484T1 (en) UNIONS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND CONCLUSIONS, AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND DISEASE
MXPA03005464A (en) Antiviral agents.
UA92181C2 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimers disease
NO20052739L (en) CCR5 antagonists as drugs
EE200300033A (en) Cyclopentanoindoles, their use in the preparation of a medicament, and the pharmaceutical composition containing them
UA90858C2 (en) Controlled-release formulations containing vardenafil
ATE404552T1 (en) SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE
UA86614C2 (en) Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
NO20093464L (en) New drug mixtures based on anti-cholinergically effective compounds and beta-mimetics
ATE361287T1 (en) NEW INDOL-2-ON DERIVATIVES
ATE402176T1 (en) PYRROLIDINE AND AZETIDINE COMPOUNDS ALSCCR5 ANTAGONISTS
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
WO2003048164A3 (en) Adenosine a2a receptor antagonists
TW200606164A (en) New compounds
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
SE0104331D0 (en) Novel compounds
TW200800984A (en) New compounds
HUP0400553A2 (en) Pharmaceutical compositions
SE0102440D0 (en) New compound
CY1110401T1 (en) PRODUCTION OF 1-PHENYLCOCARCAROXYLIC ACIDS FOR TREATMENT OF NEUROCOLOGICAL DISEASES
ATE400563T1 (en) NEW NEUROKININ ANTAGONISTS FOR USE AS MEDICINAL PRODUCTS
WO2005082884A3 (en) 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease
HUP0300032A2 (en) Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition